Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Endovascular Management of Pelvic Congestion Syndrome

NCT07735156 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-01-14
Last updated
2026-07-29

Condition(s) studied

Pelvic Congestion Syndrome

Investigational drug(s) / intervention(s)

Endovascular embolization

Endovascular embolization: Transcatheter embolization of incompetent ovarian and/or pelvic veins using standard embolic materials according to institutional practice to treat pelvic congestion syndrome.

Study summary

Pelvic congestion syndrome (PCS) is a common cause of chronic pelvic pain in women and is associated with pelvic venous insufficiency. This prospective interventional study aims to evaluate the safety and clinical effectiveness of endovascular embolization in relieving symptoms and improving quality of life in women diagnosed with PCS

Eligibility

Sex
FEMALE
Min age
17 Years
Max age
55 Years
Healthy volunteers
No
Inclusion Criteria: * Female patients aged 18 years or older. * Chronic pelvic pain for more than 6 months. * Clinical suspicion of pelvic congestion syndrome. * Imaging findings consistent with pelvic congestion syndrome on Doppler ultrasound, CT venography, MR venography, or catheter venography. * Patients willing to undergo endovascular embolization. * Written informed consent obtained Exclusion Criteria: * Pregnancy. * Active pelvic inflammatory disease. * Known pelvic malignancy. * Chronic pelvic pain due to other identifiable causes (e.g., endometriosis, large uterine fibroids). * Contraindication to iodinated contrast media. * Severe renal impairment. * Uncorrectable coagulation disorders. * Refusal to participate.

Primary outcome measure(s)

  • Improvement in pelvic pain after endovascular embolization — 6 months
    Change in pelvic pain measured using the Visual Analog Scale (VAS, 0-10), comparing baseline with 6-month follow-up. Unit of Measure: VAS score (0-10)

Trial sites (1)

FacilityCityRegionStatus
Interventional radiology unit, Sohag university hospital Sohag Sohag Governorate Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07735156 on ClinicalTrials.gov ↗ ← All trials in Egypt